Aim Atopic dermatitis (AD) is the most common chronically relapsing pruritic skin disease of children. The wet wrap therapy (WWT) with corticosteroid dilutions and moisturizers has been reported to be highly effective in AD. The aim of this study was to evaluate the efficacy of WWT in children with moderate to severe AD.

Material and Method We compared 12 AD children treated with WWT and 37 AD children treated with only conventional therapy. Topical 1% hydrocortisone (Lacticare HC 1% ™) and moisturizer (Zeroid intensive rich cream MD ™) were applied to all of 49 patients. 12 patients underwent WWT put on double layer of bandages or garments (Tubifast™), moist inner layer and a dry outer layer, for 2 hours per day in 2 weeks (figure 1). Scoring Atopic Dermatitis (SCORAD) index was measured on day 0, 7, and 14 of treatment.

• Download figure
• Open in new tab
• Download powerpoint

Abstract OP-070 Figure 1

Requirement for wet wrap therapy and clinical image of patient’s lesion. (A) Requirement for wet wrap therapy: Tubifast ™ garmenents including gloves and socks, 1% hydrocortisone (Lacticare HC 1% ™), moisturizers (Zeroid intensive rich cream MD ™) and normal saline solution. Clinical image of patient’s lesion before (B) and after (C) 2 weeks of wet wrap therapy.

Results The initial mean SCORAD index of all 49 patents was 52.3 ± 15.3 and that of 12 AD patients with wet wrap therapy (WWT+) was 58.3 ± 12.9 compared to 48.7 ± 13.6 in patients with only conventional treatment (WWT-) (table 1). Improvement in SCORAD index was significantly higher in patients with WWT than in the conventional group. In WWT+ group, the mean SCORAD index decreased from 58.3 on day 0, to 18.4 on day 7 and 12.3 on day 14. In WWT- group, the mean SCORAD index decreased from 48.7 on day 0 to 31.6 on day 7 and 19.0 on day 14 (table 1).

Conclusions Wet wrap treatment using double layer of bandages or garments (Tubifast™) with moisturizer (Zeroid intensive rich cream MD ™) and low dose topical corticosteroids, 1% hydrocortisone (Lacticare HC 1% ™) categorized class 7 potency, was highly effective in pediatric patient with moderate to severe atopic dermatitis.